Millions of people with obstructive sleep apnea (OSA) rely on CPAP machines every night. But what if a once-weekly injection could reduce the severity of sleep apnea on its own? Can tirzepatide help with sleep apnea? New research suggests the answer may be yes — and the results have turned heads in the medical community.
This article breaks down what the latest clinical trials found, who might benefit, and what it means for patients right now.
What Is Obstructive Sleep Apnea?
Obstructive sleep apnea is a condition where your throat muscles relax during sleep, causing your airway to partially or fully block. This leads to repeated pauses in breathing — sometimes hundreds of times per night.
Every pause wakes the brain just enough to restart breathing. Most people never remember these micro-arousals. But over time, this disrupted sleep raises the risk of high blood pressure, heart disease, stroke, and type 2 diabetes.
Obesity is one of the biggest drivers of OSA. Excess weight around the neck and chest puts pressure on the airway. The standard treatment is PAP (positive airway pressure) therapy, which works well, but many patients find it uncomfortable and stop using it.
Why Scientists Are Studying Tirzepatide for Sleep Apnea
Tirzepatide works on two hormone receptors — GLP-1 and GIP — and is highly effective for weight loss. Since obesity is a primary cause of OSA, researchers hypothesized that meaningful weight reduction could improve or even resolve sleep apnea in obese patients.
The question was: by how much?
To find out, Eli Lilly funded the SURMOUNT-OSA phase 3 clinical program — two large, rigorous trials that ran from June 2022 through March 2024.
What the SURMOUNT-OSA Trials Found
The trials enrolled 469 adults with moderate-to-severe OSA and obesity. Participants were split into two groups:
- Trial 1: People who were not using PAP therapy
- Trial 2: People who were already using PAP therapy and continued it during the trial
All participants received either tirzepatide (10 mg or 15 mg weekly) or a placebo for 52 weeks.
The main measurement was the apnea-hypopnea index (AHI) — the number of breathing disruptions per hour of sleep.
The results were striking.
In Trial 1, tirzepatide reduced the AHI by an average of 27.4 events per hour — compared to just 4.8 with placebo.
In Trial 2, tirzepatide reduced the AHI by 29.3 events per hour — compared to just 5.5 with placebo.
That translates to a reduction of up to nearly 63% in breathing disruptions during sleep.
Even more encouraging: up to 51.5% of participants in the tirzepatide group met the criteria for disease resolution — meaning their sleep apnea effectively cleared up.
(Source: New England Journal of Medicine, June 2024 — https://pmc.ncbi.nlm.nih.gov/articles/PMC11598664/)
Beyond Breathing: Other Improvements Seen
The trials did not just measure airway function. Tirzepatide also produced significant improvements in:
- Body weight — participants lost an average of 18–20% of their body weight.
- Systolic blood pressure — meaningfully reduced.
- Hypoxic burden — the amount of time blood oxygen dropped dangerously low during sleep.
- High-sensitivity CRP — a marker of inflammation linked to cardiovascular risk.
- Sleep quality and daytime functioning — measured by patient-reported outcomes.
These secondary benefits matter because untreated sleep apnea is linked to serious cardiovascular complications including hypertension, coronary disease, and atrial fibrillation.
(Source: Eli Lilly SURMOUNT-OSA Press Release — https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-reduced-obstructive-sleep-apnea-osa-severity)
Can Tirzepatide Help With Sleep Apnea Without PAP Therapy?
This is one of the most exciting findings from the trials.
Trial 1 specifically enrolled patients who were not using PAP therapy. Even without airway pressure support, tirzepatide alone produced dramatic reductions in AHI. This is significant because it suggests tirzepatide could be a standalone treatment option for obesity-related OSA.
Eli Lilly submitted tirzepatide to the FDA for approval as a treatment for moderate-to-severe OSA in obese patients. If approved, it would be the first pharmaceutical specifically cleared for the underlying disease itself — not just the symptoms.
Is Tirzepatide FDA-Approved for Sleep Apnea?
As of the time of this writing, tirzepatide (Zepbound) has received FDA approval for use in adults with moderate-to-severe obstructive sleep apnea and obesity. The FDA reviewed the SURMOUNT-OSA data and cleared it for this indication. Always check with your prescribing physician for the most current guidance.
(Source: ClinicalTrials.gov — SURMOUNT-OSA — https://clinicaltrials.gov/study/NCT05412004)
Who Might Benefit Most?
Based on the trial data, tirzepatide for sleep apnea appears most beneficial for:
- Adults with a BMI of 30 or above.
- Those with moderate-to-severe OSA (AHI of 15 or more events per hour).
- Patients who struggle with or refuse PAP therapy.
- People who also need weight management support.
It is less clear whether tirzepatide helps with sleep apnea that is not driven by obesity. OSA can have other structural causes (like jaw shape or nasal anatomy) that weight loss would not fix.
Getting Started With a Supervised Program
If you have been told you have sleep apnea and you also carry excess weight, speaking with a physician about tirzepatide may be worthwhile.
TirzepatideRX makes this easy. The program pairs licensed physician consultations with once-weekly tirzepatide delivered to your home — no clinic visits required.
Treatment options include:
- Monthly Plan at $399: Ongoing weekly injections with medical monitoring and no long-term commitment
- 3-Month Plan at $1,125: Full supply upfront, quarterly health check-ins, and priority support
- 6-Month Plan at $2,199: Best value, with bi-monthly physician check-ins, premium support, and nutrition coaching
Ready to explore your options? Start your program today or browse related health topics at the TirzepatideRX blog.
Conclusion
The question of whether can tirzepatide help with sleep apnea now has a clear scientific answer backed by phase 3 trials published in the New England Journal of Medicine. For those with obesity-related OSA, this medication could offer meaningful, life-changing relief
FAQ: Tirzepatide and Sleep Apnea
Can tirzepatide help with sleep apnea in people without diabetes?
Yes — the SURMOUNT-OSA trials included adults with obesity but without diabetes, and results were significantly positive.
How much does tirzepatide reduce sleep apnea?
Clinical trials showed reductions of up to 63% in breathing disruptions per hour of sleep.
Does tirzepatide replace CPAP therapy?
It may reduce the need for it in some patients, but your sleep specialist should guide any changes to your treatment plan.
How quickly does tirzepatide improve sleep apnea?
Significant improvements were seen at week 20 and continued through week 52 in the clinical trials.
Is tirzepatide approved for sleep apnea?
Yes, the FDA has approved tirzepatide (Zepbound) for moderate-to-severe OSA in adults with obesity — confirm current status with your physician.
Sources
- PMC — SURMOUNT-OSA Phase 3 Trial Full Results: https://pmc.ncbi.nlm.nih.gov/articles/PMC11598664/
- Eli Lilly Investor Press Release — SURMOUNT-OSA Detailed Results: https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-reduced-obstructive-sleep-apnea-osa-severity
- ClinicalTrials.gov — SURMOUNT-OSA Study Record: https://clinicaltrials.gov/study/NCT05412004
- ScienceDirect — Patient-Reported Outcomes in SURMOUNT-OSA: https://www.sciencedirect.com/science/article/pii/S1389945725003946
